Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial.
about
Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial AsthmaProfile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPDClinical potential of aclidinium bromide in chronic obstructive pulmonary diseaseA case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use.COPD: maximization of bronchodilation.A novel model-based approach for dose determination of glycopyrronium bromide in COPDEfficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease.Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial.Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trialEffects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study.Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design.Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)Role of once-daily glycopyrronium bromide (NVA237) in the management of COPDEfficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON studyDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study.A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyEfficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit.Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.No room to breathe: the importance of lung hyperinflation in COPD.Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease.Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.COPD symptoms in the morning: impact, evaluation and managementUmeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease.Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications and treatment.Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.Strategies for reducing the risk of cardiovascular disease in patients with chronic obstructive pulmonary disease.Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study.Long-acting muscarinic antagonists.Updates in the management of stable chronic obstructive pulmonary disease.Does Improving Exercise Capacity and Daily Activity Represent the Holistic Perspective of a New COPD Approach?When is dual bronchodilation indicated in COPD?Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).Pharmacological management of breathlessness in COPD: recent advances and hopes for the future.Pathophysiology of dyspnea in COPD.Safety of inhaled long-acting anti-muscarinic agents in COPD.Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies.Summary of the Chronic Obstructive Pulmonary Disease Clinical Practice Guideline Revised in 2014 by the Korean Academy of Tuberculosis and Respiratory Disease.
P2860
Q26780553-1C470BC3-E9DC-4F3D-85B2-DCA79C6273BAQ26825822-13A37815-C313-4120-9E4A-03CFD2DE586EQ27023223-2C35B7F2-D38B-46C2-8C09-D09114533611Q33167296-AEDB5A7C-D891-4374-8DDA-04191F3B9AA2Q34436393-3210B5FB-5B06-49AA-B3C1-2A3B22462AC1Q34502782-857EC0FE-1019-4F1D-BA25-E2E691423994Q34944547-C002B8E8-ABD5-4695-B578-155F66CCEEDBQ35135970-498CAAB8-C47A-44C6-B3A1-A4A58ABA4134Q35191130-ECED5AC2-B3E7-418C-A688-4B61EB1246C3Q35595077-592EC64B-0F66-4E9F-87AF-26A45792D6B2Q36052200-E221ADC3-E495-4035-AAFD-7B2CC3CFCD20Q36361289-0AE023CE-81E6-43A1-B345-D876EB3D4911Q36818912-84B5779D-D2B9-468B-803F-A2F3705E988FQ37069374-DEF819EF-0395-4BB0-A15F-93C58534EA4AQ37120706-DCD84E74-FCF9-40FF-BE90-EFF2EA17479FQ37247499-02E31100-1DBA-41B7-8F7E-613417597774Q37351371-F12C6FD6-C703-45CE-8076-B2F8F2EAB767Q37533170-FC8F4188-585B-4FA7-B23A-C116A28357B7Q37614103-246401DF-4516-4FB4-8C9F-2AE241B58E4EQ38051307-46484715-0809-47AC-9801-4B6EA1625650Q38057220-D29FC3BB-B745-409D-83E3-F3BA2A6BC964Q38083537-0D66B2E4-4D7F-449E-AE5E-2B4875F06752Q38107178-52E8682A-2617-4E4E-A679-9A3D79BA4357Q38131050-777F4325-0190-4BA1-ABD3-41E9230CBC4CQ38154294-254165E6-6A3B-49F4-AF35-A6BC9D6AF48DQ38218619-945FA153-65F8-4E2A-A25A-1CB5377F5BDCQ38243468-65CFE8B8-49D3-4BDD-ABA5-84AE1C30903DQ38303157-76678437-FDAD-49A3-8406-826C883B19DAQ38345525-D95EC51F-D042-4C92-93A5-A6DEBB93D355Q38371555-B3809AC1-59D3-4C0F-86A8-47871F4498B3Q38537326-4CB428B5-6513-4730-B2CC-3022D4F09A14Q38578596-AC89CAFC-CDCD-4147-9274-5263702417ABQ38604749-FDDD1C1B-F1BF-4EF7-8949-938530DE716FQ38641441-CFA7D3CC-DE9C-4419-AA85-DD490F71C2B2Q38660895-58A71EFC-975C-45A3-9018-081902808B1AQ38817813-81161F63-73A5-4389-81D3-1DF436CD3758Q39170919-75EF9FD2-C304-4923-996C-05D90F70A9EAQ39232425-EF375E2A-C2D6-467F-86FB-71DC6207D666Q39627403-57876A8C-A425-458A-825E-489B50F8F42AQ40106829-77FBD80B-FD96-46C1-86D5-391B7F2FC463
P2860
Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Once-daily NVA237 improves exe ...... ts with COPD: the GLOW3 trial.
@ast
Once-daily NVA237 improves exe ...... ts with COPD: the GLOW3 trial.
@en
type
label
Once-daily NVA237 improves exe ...... ts with COPD: the GLOW3 trial.
@ast
Once-daily NVA237 improves exe ...... ts with COPD: the GLOW3 trial.
@en
prefLabel
Once-daily NVA237 improves exe ...... ts with COPD: the GLOW3 trial.
@ast
Once-daily NVA237 improves exe ...... ts with COPD: the GLOW3 trial.
@en
P2093
P2860
P356
P1476
Once-daily NVA237 improves exe ...... ts with COPD: the GLOW3 trial.
@en
P2093
Anton Drollmann
Dave Singh
Kai M Beeh
Lilla Di Scala
P2860
P304
P356
10.2147/COPD.S32451
P407
P577
2012-07-31T00:00:00Z